The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Open accessAbstract
The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in the liver in combination with metabolic dysfunction in the form of overweight or obesity and insulin resistance. It is also associated with an increased cardiovascular disease risk, including hypertension and atherosclerosis. Hepatic lipid metabolism is regulated by a combination of the uptake and export of fatty acids, de novo lipogenesis, and fat utilization by β-oxidation. When the balance between these pathways is altered, hepatic lipid accumulation commences, and long-term activation of inflammatory and fibrotic pathways can progress to worsen the liver disease. This review discusses the details of the molecular mechanisms regulating hepatic lipids and the emerging therapies targeting these pathways as potential future treatments for MAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W. (2004) · Hypertension · doi:10.1161/01.hyp.0000123072.34629.57 · Cited by 1,073
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Epidemiology of Non-Alcoholic Fatty Liver Disease
Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026
Selective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D., & Uyeda, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401516101 · Cited by 785
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · cited 1×
“In addition, increased circulating insulin levels stimulate hepatic de novo lipogenesis in patients with MAFLD [12].”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739 · cited 1×
“Also, its long-term use has been linked with vitamin B12 deficiency [15,90].”
BackgroundLiver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310798 · Cited by 736
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 736
Alcoholic Liver Disease: Pathogenesis and Current Management
Osna, N. (2017) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v38.2.01 · Cited by 724
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Hepatology · doi:10.1002/hep.23623 · Cited by 564
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Sanders, F. W. B., & Griffin, J. L. (2016) · Biological Reviews · doi:10.1111/brv.12178 · Cited by 539
Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada, P., González-Rodríguez, Á., García-Monzón, C., & Valverde, Á. M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03003-w · Cited by 518
Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated With Diet-Induced Obesity
Koonen, D. P. Y., Jacobs, R. L., Febbraio, M., Young, M. E., Soltys, C.-L. M., Ong, H., Vance, D. E., & Dyck, J. R. B. (2007) · Diabetes · doi:10.2337/db07-0907 · Cited by 511
Zang, M., Zuccollo, A., Hou, X., Nagata, D., Walsh, K., Herscovitz, H., Brecher, P., Ruderman, N. B., & Cohen, R. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408149200 · Cited by 453
Miquilena-Colina, M. E., Lima-Cabello, E., Sánchez-Campos, S., García-Mediavilla, M. V., Fernández-Bermejo, M., Lozano-Rodríguez, T., Vargas-Castrillón, J., Buqué, X., Ochoa, B., Aspichueta, P., et al. (2011) · Gut · doi:10.1136/gut.2010.222844 · Cited by 451
Liver-Specific Inhibition of ChREBP Improves Hepatic Steatosis and Insulin Resistance in ob/ob Mice
Dentin, R., Benhamed, F., Hainault, I., Fauveau, V., Foufelle, F., Dyck, J. R. B., Girard, J., & Postic, C. (2006) · Diabetes · doi:10.2337/db06-0200 · Cited by 433
Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes
Joshi-Barve, S., Barve, S. S., Amancherla, K., Gobejishvili, L., Hill, D., Cave, M., Hote, P., & McClain, C. J. (2007) · Hepatology · doi:10.1002/hep.21752 · Cited by 406
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Ota, T., Gayet, C., & Ginsberg, H. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32752 · Cited by 376
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Emerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Yoon, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.004 · Cited by 336
Pathogenesis and Prevention of Hepatic Steatosis.
Nassir, F., Rector, R. S., Hammoud, G. M., & Ibdah, J. A. (2015) · PubMed · Cited by 336
Apolipoprotein synthesis in nonalcoholic steatohepatitis
Charlton, M., Sreekumar, R., Rasmussen, D., Lindor, K., & Nair, S. K. (2002) · Hepatology · doi:10.1053/jhep.2002.32527 · Cited by 333
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Newberry, E. P., Xie, Y., Kennedy, S., Han, X., Buhman, K. K., Luo, J., Gross, R. W., & Davidson, N. O. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309377200 · Cited by 303
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Evolution of NAFLD and Its Management
Mundi, M. S., Velapati, S., Patel, J., Kellogg, T. A., Abu Dayyeh, B. K., & Hurt, R. T. (2020) · Nutrition in Clinical Practice · doi:10.1002/ncp.10449 · Cited by 285
Doege, H., Baillie, R. A., Ortegon, A. M., Tsang, B., Wu, Q., Punreddy, S., Hirsch, D., Watson, N., Gimeno, R. E., & Stahl, A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.006 · Cited by 279
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Recent insights into the biological functions of liver fatty acid binding protein 1
Wang, G., Bonkovsky, H. L., de Lemos, A., & Burczynski, F. J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r056705 · Cited by 273
Goedeke, L., Bates, J., Vatner, D. F., Perry, R. J., Wang, T., Ramirez, R., Li, L., Ellis, M. W., Zhang, D., Wong, K. E., et al. (2018) · Hepatology · doi:10.1002/hep.30097 · Cited by 259
Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMJ · doi:10.1136/bmj.l5367 · Cited by 254
Bilirubin in the Liver–Gut Signaling Axis
Hamoud, A.-R., Weaver, L., Stec, D. E., & Hinds, T. D. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.01.002 · Cited by 254
Self-citationShirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Shiri-Sverdlov, R., Wouters, K., Gorp, P. J. V., Gijbels, M. J., Noel, B., Buffat, L., Staels, B., Maeda, N., Bilsen, M. V., & Hofker, M. H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.033 · Cited by 241
Seki, E., Tsutsui, H., Nakano, H., Tsuji, N. M., Hoshino, K., Adachi, O., Adachi, K., Futatsugi, S., Kuida, K., Takeuchi, O., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2651 · Cited by 231
Bilirubin as a metabolic hormone: the physiological relevance of low levels
Creeden, J. F., Gordon, D. M., Stec, D. E., & Hinds, T. D. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00405.2020 · Cited by 230
Self-citationCalle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01489-1 · Cited by 219
Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 215
Newberry, E. P., Xie, Y., Kennedy, S. M., Luo, J., & Davidson, N. O. (2006) · Hepatology · doi:10.1002/hep.21369 · Cited by 204
Jojima, T., Tomotsune, T., Iijima, T., Akimoto, K., Suzuki, K., & Aso, Y. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0169-x · Cited by 202
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199
Woo, S.-L., Xu, H., Li, H., Zhao, Y., Hu, X., Zhao, J., Guo, X., Guo, T., Botchlett, R., Qi, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091111 · Cited by 194
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191
Bilirubin Binding to PPARα Inhibits Lipid Accumulation
Stec, D. E., John, K., Trabbic, C. J., Luniwal, A., Hankins, M. W., Baum, J., & Hinds, T. D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153427 · Cited by 191
Self-citationWhat is the real function of the liver 'function' tests?
Hall, P., & Cash, J. (2012) · PubMed Central · Cited by 190
Negi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Ge, X., Zheng, L., Wang, M., Du, Y., & Jiang, J. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-036663 · Cited by 188
Taheri, H., Malek, M., Ismail-Beigi, F., Zamani, F., Sohrabi, M., Reza babaei, M., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 188
Shiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., Yamaguchi, S., Ogasawara, N., Katoh, M., Itoh, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19658-7 · Cited by 175
Iizuka, K., Takao, K., & Yabe, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.587189 · Cited by 174
Fraile, J. M., Palliyil, S., Barelle, C. J., Porter, A. J., & Kovaleva, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s315724 · Cited by 172
Doege, H., Grimm, D., Falcon, A., Tsang, B., Storm, T. A., Xu, H., Ortegon, A. M., Kazantzis, M., Kay, M. A., & Stahl, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803510200 · Cited by 169
Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 168
Knebel, B., Haas, J., Hartwig, S., Jacob, S., Köllmer, C., Nitzgen, U., Muller–Wieland, D., & Kotzka, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031812 · Cited by 162 · cited 1×
“Hepatocyte-specific overexpression of SREBP-1c results in the upregulation of key enzymes in de novo lipogenesis resulting in hepatic lipid accumulation [67].”
BackgroundHarano, Y., Yasui, K., Toyama, T., Nakajima, T., Mitsuyoshi, H., Mimani, M., Hirasawa, T., Itoh, Y., & Okanoue, T. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01265.x · Cited by 161
Meta‐analysis: insulin sensitizers for the treatment of non‐alcoholic steatohepatitis
Rakoski, M. O., Singal, A. G., Rogers, M. A. M., & Conjeevaram, H. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04467.x · Cited by 158
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 156
Vitamin E and nonalcoholic fatty liver disease
Pacana, T., & Sanyal, A. J. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328357f747 · Cited by 153
Romero‐Gómez, M., Diago, M., Andrade, R. J., Calleja, J. L., Salmerón, J., Fernández‐Rodríguez, C., Sola, R. L., García‐Samaniego, J., Herrerías, J. M., de la Mata, M., et al. (2009) · Hepatology · doi:10.1002/hep.23206 · Cited by 153
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
JOY, T. R., McKenzie, C. A., Tirona, R. G., Summers, K. L., Seney, S. L., Chakrabarti, S., Malhotra, N., & Beaton, M. D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.141 · Cited by 152
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
Kostapanos, M. S., Κεή, Α., & Elisaf, M. S. (2013) · World Journal of Hepatology · doi:10.4254/wjh.v5.i9.470 · Cited by 147
Kannt, A., Wohlfart, P., Madsen, A. N., Veidal, S. S., Feigh, M., & Schmoll, D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15427 · Cited by 146
Biliverdin reductase isozymes in metabolism
O’Brien, L., Hosick, P. A., John, K., Stec, D. E., & Hinds, T. D. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.02.001 · Cited by 144
Self-citationFibrates for secondary prevention of cardiovascular disease and stroke
Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142
Wettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 140
Tølbøl, K. S., Kristiansen, M. N. B., Hansen, H. H., Veidal, S. S., Rigbolt, K. T. G., Gillum, M. P., Jelsing, J., Vrang, N., & Feigh, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i2.179 · Cited by 140
Cheriyath, P. (2010) · Journal of Clinical Medicine Research · doi:10.4021/jocmr425w · Cited by 139
Hinds, T. D., Burns, K. A., Hosick, P. A., McBeth, L., Nestor‐Kalinoski, A. L., Drummond, H. A., AlAmodi, A. A., Hankins, M. W., Heuvel, J. P. V., & Stec, D. E. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.731703 · Cited by 138
Self-citationKaul, U., Parmar, D., Manjunath, K., Shah, M., Parmar, K., Patil, K. P., & Jaiswal, A. D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0884-3 · Cited by 137
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 133
The glucocorticoid receptor: cause of or cure for obesity?
John, K., Marino, J., Sánchez, E., & Hinds, T. (2016) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.00478.2015 · Cited by 131
Self-citationEffects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Yilmaz, Y. N., Yönal, O., Deyneli, O., Çelikel, Ç., Kalaycı, C., & Duman, D. (2012) · PubMed · Cited by 131
Kumar, D. P., Caffrey, R., Marioneaux, J., Santhekadur, P. K., Bhat, M., Alonso, C., Koduru, S. V., Philip, B., Jain, M. R., Giri, S. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66458-z · Cited by 130
Wong, V. W., Wong, G. L., Tsang, S. W., Hui, A., Chan, A. W. H., Choi, P. C., Chim, A. M.-L., CHU, S., Chan, F. K. L., Sung, J. J. �., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03896.x · Cited by 129
Chang, G., Wu, Y., Chiu, Y., Chen, W., Liao, J., Hsu, H., Chao, T., Hung, S., & Mao, F. C. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00427.x · Cited by 127
Mukai, T., Egawa, M., Takeuchi, T., Yamashita, H., & Kusudo, T. (2017) · FEBS Open Bio · doi:10.1002/2211-5463.12240 · Cited by 126
Liu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3292 · Cited by 124
Bilirubin, a Cardiometabolic Signaling Molecule
Hinds, T. D., & Stec, D. E. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11130 · Cited by 123
Self-citationSerum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
Kwak, M., Kim, D., Chung, G. E., Kang, S. J., Park, M. J., Kim, Y. J., Yoon, J., & Lee, H.-S. (2012) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2012.18.4.383 · Cited by 121
Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity
Stec, D. E., Gordon, D. M., Hipp, J., Hong, S., Mitchell, Z. L., Franco, N. R., Robison, J., Anderson, C. D., Stec, D. F., & Hinds, T. D. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2019 · Cited by 116
Self-citationHan, S. S., Na, K. Y., Chae, D., Kim, Y. S., Kim, S., & Chin, H. J. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.133 · Cited by 110
Moreno-Fernandez, M. E., Giles, D. A., Stankiewicz, T. E., Sheridan, R., Karns, R., Cappelletti, M., Lampe, K., Mukherjee, R., Sina, C., Sallese, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93626 · Cited by 106
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106
Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults
Choi, S. H., Yun, K. E., & Choi, H. J. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.03.001 · Cited by 105
Duseja, A. K., Das, A., Dhiman, R. K., Chawla, Y. K., Thumburu, K. K., Bhadada, S. K., & Bhansali, A. K. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31902-7 · Cited by 103
Biliverdin reductase and bilirubin in hepatic disease
Weaver, L., Hamoud, A.-R. A., Stec, D. E., & Hinds, T. D. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00026.2018 · Cited by 103
Self-citationGordon, D. M., Neifer, K. L., Hamoud, A.-R. A., Hawk, C. F., Nestor‐Kalinoski, A. L., Miruzzi, S. A., Morran, M. P., Adeosun, S. O., Sarver, J. G., Erhardt, P., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013700 · Cited by 103
Self-citationEmpagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Benetti, E., Mastrocola, R., Vitarelli, G., Cutrìn, J. C., Nigro, D., Chiazza, F., Mayoux, E., Collino, M., & Fantozzi, R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235069 · Cited by 102
Kim, N. H., Han, K. H., Choi, J., Lee, J., & Kim, S. G. (2019) · BMJ · doi:10.1136/bmj.l5125 · Cited by 102
Jain, M. R., Giri, S. R., Trivedi, C. J., Bhoi, B., Rath, A., Vanage, G. R., Vyas, P., Ranvir, R. K., & Patel, P. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.136 · Cited by 96
Hinds, T. D., Hosick, P. A., Chen, S., Tukey, R. H., Hankins, M. W., Nestor‐Kalinoski, A. L., & Stec, D. E. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00396.2016 · Cited by 95
Self-citationWu, Y., Li, M., Xu, M., Bi, Y., Xiaoying, L. I., Chen, Y., Ning, G., & Wang, W. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00138.x · Cited by 94
Marino, J. S., Stechschulte, L. A., Stec, D. E., Nestor‐Kalinoski, A. L., Coleman, S., & Hinds, T. D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.752311 · Cited by 94
Self-citationSteinberg, G. R., Macaulay, S. L., Febbraio, M. A., & Kemp, B. E. (2006) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y06-005 · Cited by 93
Hinds, T. D., Creeden, J. F., Gordon, D. M., Stec, D. F., Donald, M. C., & Stec, D. E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.594574 · Cited by 93
Self-citationPhysical activity as a treatment of non-alcoholic fatty liver disease: A systematic review
Whitsett, M. P. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i16.2041 · Cited by 90
Hirata, T., Tomita, K., Kawai, T., Yokoyama, H., Shimada, A., Kikuchi, M., Hirose, H., Ebinuma, H., Irie, J., Ojiro, K., et al. (2013) · International Journal of Endocrinology · doi:10.1155/2013/587140 · Cited by 87
Thomas, D. T., DelCimmuto, N. R., Flack, K. D., Stec, D. E., & Hinds, T. D. (2022) · Antioxidants · doi:10.3390/antiox11020179 · Cited by 84
Self-citationGoyal, O., Nohria, S., Goyal, P., Kaur, J., Sharma, S., Sood, A., & Chhina, R. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-78342-x · Cited by 83
MRI Steatosis Grading: Development and Initial Validation of a Color Mapping System
Qayyum, A., Nystrom, M. M., Noworolski, S. M., Chu, P., Mohanty, A., & Merriman, R. B. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.6729 · Cited by 83
Tarantino, G., Citro, V., Balsano, C., & Capone, D. (2020) · Diagnostics · doi:10.3390/diagnostics10060395 · Cited by 83
PPAR α in Obesity: Sex Difference and Estrogen Involvement
Yoon, M. (2010) · PPAR Research · doi:10.1155/2010/584296 · Cited by 80
Burz, S. D., Monnoye, M., Philippe, C., Farin, W., Ratziu, V., Strozzi, F., Paillarse, J.-M., Chêne, L., Blottière, H. M., & Gérard, P. (2021) · Microorganisms · doi:10.3390/microorganisms9010199 · Cited by 79
Luong, X. G., Stevens, S., Jekle, A., Lin, T., Gupta, K., Misner, D., Chanda, S. M., Mukherjee, S., Williams, C., Stoycheva, A. D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240338 · Cited by 77
Hinds, T. D., Kipp, Z. A., Xu, M., Yiannikouris, F. B., Morris, A. J., Stec, D. F., Wahli, W., & Stec, D. E. (2021) · Cells · doi:10.3390/cells11010004 · Cited by 76
Self-citationFKBP51 and the molecular chaperoning of metabolism
Smedlund, K., Sánchez, E. R., & Hinds, T. D. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.08.003 · Cited by 75
Self-citationPrediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines
Jamali, R., Arj, A., Razavizade, M., & Aarabi, M. H. (2016) · Medicine · doi:10.1097/md.0000000000002630 · Cited by 74
Abdel-Maboud, M., Menshawy, A., Menshawy, E., Emara, A., Alshandidy, M., & Eid, M. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820974917 · Cited by 74
Adeosun, S. O., Gordon, D. M., Weeks, M. F., Moore, K. H., Hall, J. E., Hinds, T. D., & Stec, D. E. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00495.2017 · Cited by 73
Self-citationShindo, N., Fujisawa, T., Sugimoto, K., Nojima, K., Fukai, A., Yoshikawa, Y., Wang, X., Yasuda, O., Ikegami, H., & Rakugi, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.033 · Cited by 72
Kim, M. Y., Cho, M.-Y., Baik, S. K., Jeong, P. H., Suk, K. T., Jang, Y. O., Yea, C. J., Kim, J. W., Kim, H. S., Kwon, S. O., et al. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02774.x · Cited by 71
Gordon, D. M., Blomquist, T. M., Miruzzi, S. A., McCullumsmith, R. E., Stec, D. E., & Hinds, T. D. (2019) · Physiological Genomics · doi:10.1152/physiolgenomics.00028.2019 · Cited by 71
Self-citationThyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD
Sinha, R. A., & Yen, P. M. (2016) · Cell & Bioscience · doi:10.1186/s13578-016-0113-7 · Cited by 68
Variants in the UGT1A1 Gene and the Risk of Pediatric Nonalcoholic Fatty Liver Disease
Lin, Y., Chang, P., Hu, F., Chang, M., & Ni, Y. (2009) · PEDIATRICS · doi:10.1542/peds.2008-3087 · Cited by 66
Bilirubin Safeguards Cardiorenal and Metabolic Diseases: a Protective Role in Health
Hinds, T. D., & Stec, D. E. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0994-z · Cited by 65
Self-citationSalomone, F., Volti, G. L., Rosso, C., Grosso, G., & Bugianesi, E. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12155 · Cited by 61
Cone, C. J., Bachyrycz, A. M., & Murata, G. H. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p099 · Cited by 61
Lu, Y., Chang, C., Wang, C.-P., Hung, W., Tsai, I., Tang, W.-H., Wu, C., Wei, C., Chung, F., Lee, Y., et al. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.40417 · Cited by 61
Jo, J., Yun, J. E., Hee-Yeon, L., Kimm, H., & Jee, S. H. (2010) · Endocrine · doi:10.1007/s12020-010-9417-2 · Cited by 59
Unconjugated hyperbilirubinemia is inversely associated with non‐alcoholic steatohepatitis (NASH)
Hjelkrem, M., Morales, A. L., Williams, C. D., & Harrison, S. A. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05114.x · Cited by 58
Serum Bilirubin Level Is Inversely Associated With Nonalcoholic Steatohepatitis in Children
Puri, K., Nobili, V., Melville, K., Corte, C. D., Sartorelli, M. R., López, R., Feldstein, A. E., & Alkhouri, N. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318291fefe · Cited by 57
Shao, N., Yu, X., Ma, X., Lin, W., Hao, M., & Kuang, H. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/1864307 · Cited by 57
Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease
Stec, D. E., & Hinds, T. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249493 · Cited by 56
Self-citationSayari, S., Neishaboori, H., & Jameshorani, M. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0006 · Cited by 55
Metformin-Induced Hepatotoxicity
Miralles-Linares, F., Puerta-Fernandez, S., Bernal-López, M. R., Tinahones, F. J., Andrade, R. J., & Gómez-Huelgas, R. (2012) · Diabetes Care · doi:10.2337/dc11-2306 · Cited by 53
Auinger, A., Valenti, L. V. C., Pfeuffer, M., Helwig, U., Herrmann, J. E., Fracanzani, A. L., Dongiovanni, P., Fargion, S. R., Schrezenmeir, J., & Rubin, D. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1267186 · Cited by 53
Creeden, J. F., Kipp, Z. A., Xu, M., Flight, R. M., Moseley, H., Martinez, G. J., Lee, W., Alganem, K., Imami, A. S., McMullen, M. R., et al. (2022) · Hepatology · doi:10.1002/hep.32467 · Cited by 53
Self-citationMölzer, C., Wallner, M., Kern, C., Tosevska, A., Schwarz, U., Zadnikar, R., Doberer, D., Marculescu, R., & Wagner, K. (2016) · Scientific Reports · doi:10.1038/srep30051 · Cited by 52
Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?
Hinds, T. D., Adeosun, S. O., AlAmodi, A. A., & Stec, D. E. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.08.013 · Cited by 52
Self-citationSundararaghavan, V. L., Sindhwani, P., & Hinds, T. D. (2016) · Oncotarget · doi:10.18632/oncotarget.12277 · Cited by 51
Self-citationGordon, D. M., Hong, S. H., Kipp, Z. A., & Hinds, T. D. (2021) · Molecules · doi:10.3390/molecules26102975 · Cited by 51
Self-citationStec, D. E., Gordon, D. M., Nestor-Kalinoski, A. L., Donald, M. C., Mitchell, Z. L., Creeden, J. F., & Hinds, T. D. (2020) · Biomolecules · doi:10.3390/biom10030387 · Cited by 50
Self-citationTakei, K., Han, S., Murayama, Y., Satoh, A., Oikawa, F., Ohno, H., Osaki, Y., Matsuzaka, T., Sekiya, M., IWASAKI, H. O., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12621 · Cited by 50
Zhang, D., Ma, Y., Liu, J., Deng, Y., Zhou, B., Wen, Y., Li, M., Wen, D.-Y., Ying, Y., Luo, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.689111 · Cited by 48
Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis
Wang, C., Yan, Y., Hu, L. T., Zhao, L., Yang, P., Moorhead, J. F., Varghese, Z., Chen, Y., & Ruan, X. Z. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.103 · Cited by 47
Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model
Buttet, M., Poirier, H., Traynard, V., Kévin, G., Tran, T. T. T., Sundaresan, S., Besnard, P., Abumrad, N. A., & Niot, I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145626 · Cited by 46
Akbari, R., Behdarvand, T., Afarin, R., Yaghooti, H., Jalali, M. T., & Mohammadtaghvaei, N. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00524-8 · Cited by 46
Inhibition of the Actions of Peroxisome Proliferator‐activated Receptor α on Obesity by Estrogen
Jeong, S., & Yoon, M. (2007) · Obesity · doi:10.1038/oby.2007.171 · Cited by 45
Gordon, D. M., Adeosun, S. O., Ngwudike, S. I., Anderson, C. D., Hall, J. E., Hinds, T. D., & Stec, D. E. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108072 · Cited by 45
Self-citationBilirubin, a new therapeutic for kidney transplant?
Sundararaghavan, V. L., Binepal, S., Stec, D. E., Sindhwani, P., & Hinds, T. D. (2018) · Transplantation Reviews · doi:10.1016/j.trre.2018.06.003 · Cited by 44
Self-citationPeng, X. E., Wu, Y., Lu, Q., Hu, Z. J., & Xu, L. (2013) · Liver International · doi:10.1111/liv.12220 · Cited by 43
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes
Qiang, G., Zhang, L., Yang, X., Qi, X., Shi, L., Zhang, H., Chen, B., Li, X., Zu, M., Zhou, D., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.04.028 · Cited by 43
Wang, C., Leung, C.-H., Liu, S.-C., & Chung, C.-H. (2006) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60202-3 · Cited by 41
Inverse Association Between Total Bilirubin and Metabolic Syndrome in Rural Korean Women
Kwon, K.-M., Kam, J.-H., Kim, M. Y., Kim, M., Chung, C. H., Kim, J.-K., Linton, J. A., Eom, A., Koh, S. B., & Kang, H. (2011) · Journal of Women s Health · doi:10.1089/jwh.2010.2453 · Cited by 40
PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis
Hu, X., Tanaka, N., Guo, R., Yu, L., Nakajima, T., Gonzalez, F. J., & Aoyama, T. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.09.015 · Cited by 40
Wang, C.-H., Liu, H.-M., Chang, Z., Huang, T., & Lee, T.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157841 · Cited by 37
van der Graaff, D., Chotkoe, S., Winter, B. Y. D., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100412 · Cited by 37
A Novel Fluorescence-Based Assay for the Measurement of Biliverdin Reductase Activity
Adeosun, S. O., Moore, K. H., Lang, D., Nwaneri, A. C., Hinds, T. D., & Stec, D. E. (2017) · doi:10.20455/ros.2018.809 · Cited by 36
Self-citationKunutsor, S. K., Frysz, M., Verweij, N., Kieneker, L. M., Bakker, S. J. L., & Dullaart, R. P. F. (2019) · European Journal of Epidemiology · doi:10.1007/s10654-019-00589-0 · Cited by 36
Hinds, T. D., Creeden, J. F., Gordon, D. M., Spegele, A. C., Britton, S. L., Koch, L. G., & Stec, D. E. (2020) · Antioxidants · doi:10.3390/antiox9090889 · Cited by 36
Self-citationDeciphering the Roles of Thiazolidinediones and PPAR γ in Bladder Cancer
Chiu, M., McBeth, L., Sindhwani, P., & Hinds, T. D. (2017) · PPAR Research · doi:10.1155/2017/4810672 · Cited by 35
Self-citationNaderali, E. K., Fatani, S. H., Itua, I., & Wong, C. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s17376 · Cited by 34
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Sofogianni, A., Filippidis, A., Chrysavgis, L., Tziomalos, K., & Cholongitas, E. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.493 · Cited by 33
Baron, M., Leroyer, A. S., Majd, Z., Lalloyer, F., Vallez, E., Bantubungi, K., Chinetti, G., Delerive, P., Boulanger, C. M., Staels, B., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.03.009 · Cited by 31
Tao, X., He, H., Peng, J., Xu, R., Fu, J., Hu, Y., Li, L., Yang, X., Feng, X.-L., Zhang, C., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106004 · Cited by 31
Down-Regulation of Insulin Receptors in Postnecrotic Cirrhosis of Liver*
TENG, C. S., Ho, P. W. M., & YEUNG, T. T. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-3-524 · Cited by 30
van der Veen, J. N., Lingrell, S., Gao, X., Takawale, A. R., Kassiri, Z., Vance, D. E., & Jacobs, R. L. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m070631 · Cited by 30
Tamura, Y. O., Sugama, J., Iwasaki, S., Sasaki, M., Yasuno, H., Aoyama, K., Watanabe, M., Erion, D. M., & Yashiro, H. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000786 · Cited by 29
Yavarow, Z. A., Kang, H., Waskowicz, L. R., Bay, B., Young, S. P., Yen, P. M., & Koeberl, D. D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz290 · Cited by 28
Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
van den Hoek, A. M., Verschuren, L., Caspers, M. P. M., Worms, N., Menke, A. L., & Princen, H. M. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-83974-8 · Cited by 27
Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
Yen, F., Lai, J., Wei, J. C., Chiu, L., Hsu, C., Hou, M., & Hwu, C. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01773-x · Cited by 26
Protective effect of fenofibrate against high‐fat–high‐fructose diet induced non‐obese NAFLD in rats
Abdelmoneim, D., El‐Adl, M., El‐Sayed, G., & Said, E. S. E. S. E. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12597 · Cited by 25
Eguchi, A., Iwasa, M., Yamada, M., Tamai, Y., Shigefuku, R., Hasegawa, H., HIROKAWA, Y. S., Hayashi, A., Okuno, K., Matsushita, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1971 · Cited by 24
Saini, N., Black, P. N., Montefusco, D. J., & Dirusso, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.055 · Cited by 23
Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway
Shen, T., Xu, B., Lei, T., Chen, L., Zhang, C., & Ni, Z. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6554 · Cited by 23
Verbeek, J., Spincemaille, P., Vanhorebeek, I., den Berghe, G. V., Elst, I. V., Windmolders, P., van Pelt, J. F., der Merwe, V., Bédossa, P., Nevens, F., et al. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0432-7 · Cited by 22
Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease
Saryusz‐Wolska, M., Szymańska‐Garbacz, E., Jabłkowski, M., Białkowska, J., Pawłowski, M., Kwiecińska, E., Omulecka, A., Borkowska, A., Ignaczak, A., Loba, J., et al. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1023 · Cited by 21
Cengiz, M., Özenirler, S., & Kocabıyık, M. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000502 · Cited by 21
Hinds, T. D., Stechschulte, L. A., Elkhairi, F., & Sanchez, E. R. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.76 · Cited by 20
Self-citationHinds, T. D., John, K., McBeth, L., Trabbic, C. J., & Sánchez, E. R. (2016) · PPAR Research · doi:10.1155/2016/6218637 · Cited by 16
Self-citationBilirubin: A Ligand of the PPARα Nuclear Receptor
Hong, S., Gordon, D. M., Stec, D. E., & Hinds, T. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-78315-0_17 · Cited by 15
Self-citationYu, F., Takahashi, T., Moriya, J., Kawaura, K., Yamakawa, J.-I., Kusaka, K., Itoh, T., Sumino, H., Morimoto, S., & Kanda, T. (2006) · Journal of International Medical Research · doi:10.1177/147323000603400309 · Cited by 13
Zhang, D., Niu, S.-Z., Ma, Y., Chen, H., Yu, W., Li, M., Zhou, B., Deng, Y., Shi, C., Pu, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770652 · Cited by 10
17β-estradiol inhibits PPARα of skeletal muscle
Lee, H., & Yoon, M. (2013) · Animal Cells and Systems · doi:10.1080/19768354.2013.831772 · Cited by 9
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
Chen, L., Zhang, X., Zhang, L. R., & Zheng, D. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s262284 · Cited by 8
Petrides, A. S., Paßlack, W., Reinauer, H., Stremmel, W., & Strohmeyer, G. W. (1987) · Journal of Molecular Medicine · doi:10.1007/bf01737009 · Cited by 7
Oliveros-Montiel, A., Santos‐López, G., & Sedeño-Monge, V. (2020) · PubMed · Cited by 4
Cited by
Duan, M., Zhao, X., Li, S., Miao, G., Bai, L., Zhang, Q., Yang, W., & Zhao, X. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02334-8 · Cited by 236
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
Myint, M., Oppedisano, F., De Giorgi, V., Kim, B.-M., Marincola, F. M., Alter, H. J., & Nesci, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04627-0 · Cited by 61
Lin, B., Wu, T., Nasb, M., Li, Z., & Chen, N. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.02.017 · Cited by 26
The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease
Shen, Q., Yang, M., Wang, S., Chen, X., Chen, S., Zhang, R., Xiong, Z., & Leng, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1374644 · Cited by 15
Metadata
- Authors
- Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2022-09
- Volume
- 136
- Issue
- 18
- Pages
- 1347-1366
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W4296803763
- Cited by
- 370
- References
- 197
- FWCI
- 41.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.